Cash and Cash Equivalents (USD, thousands)

Short-term Marketable Securities (USD, thousands)

Receivables from Collaborative Arrangements (USD, thousands)

Receivables from Milestones and Royalty Assets (USD, thousands)

Other Prepaid and Current Assets (USD, thousands)

Total Current Assets (USD, thousands)

Property and Equipment, Net (USD, thousands)

Operating Lease Assets (USD, thousands)

Future Contingent Milestone and Royalty Assets (USD, thousands)

Restricted Cash (USD, thousands)

Other Assets (USD, thousands)

Total Assets (USD, thousands)

Total Current Liabilities (USD, thousands)

Long-term Operating Lease Liabilities (USD, thousands)

Future Royalty Payment Contingency (USD, thousands)

Unrecognized Tax Benefits (USD, thousands)

Other Long-term Liabilities (USD, thousands)

Total Shareholders’ Equity (USD, thousands)

Total Liabilities and Shareholders’ Equity (USD, thousands)

2faff8b0fff2086d0daf61dda61970c4d8d9423af905f6bc633f4206fca23fca

Total Revenues (USD, thousands)

Viatris collaboration agreement Revenue (USD, thousands)

Total Expenses (USD, thousands)

Research and Development Expenses (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Interest Expense (Non-cash) (USD, thousands)

Interest and Other Income, Net (USD, thousands)

Loss Before Income Taxes (USD, thousands)

Provision for Income Tax Expense (USD, thousands)

Net Loss (USD, thousands)

Net Loss per Share - Basic and Diluted (USD)

796cb13fb29bafe6d2179b92e83333360cd0a9a22adf2e781c6fcaf3971322ec

Hospital volumes for YUPELRI growth (percentage)

a66a78816d04b62a53cbd72c21ca93cb6faee92da8f7758663a60e9dd52f1ae9

Net cash used in operating activities (USD, thousands)

Net cash provided by investing activities (USD, thousands)

Net cash (used in) provided by financing activities (USD, thousands)

Net increase in cash, cash equivalents, and restricted cash (USD, thousands)

Cash paid for interest (USD, thousands)

Cash paid (received) for income taxes, net (USD, thousands)

Cash, cash equivalents, and restricted cash at beginning of period (USD, thousands)

Cash, cash equivalents, and restricted cash at end of period (USD, thousands)

8821373300734a79ddd56f5242352630b2ade91ded8e3b103362300619093d9b

United States

Europe

Total Revenue

8172f4823d9501af734269be8992a0fe14e699fd828843599faaec20f0038590

Viatris Collaboration

Collaboration Revenue

Licensing Revenue

edd24bcf938ccf882cffd14dcd1767beb11f66d3eae7dcff4561aff2284b77fa

Theravance Biopharma (TBPH)

Financials